CB2 Insights Announces Quarterly Revenue of $2.93 million for Q1 2020. EBITDA Nears Breakeven. - Seite 2

3 months ended	31-Mar-2020	31-Mar-2019
Revenue	$2,932,026	$2,849,811
Gross Profit	$1,901,695	$2,194,123
Gross Margin	64.9%	76.9%
Operating Expenses	$3,046,820	$3,194,089
Net Loss	-$983,181	-$2,146,203
Adjusted EBITDA loss	-$603,134	-$712,252
Basic and diluted net loss per common share	$0.011	$0.031
Weighted average common shares outstanding – basic and diluted	90,620,904	68,963,299

Highlights from Q2 2020:

• In April 2020, the Company launched Skylight Health Group (“SHG”) as part of its clinical operations in the US to focus on integrated healthcare and providing low cost insurable services to patients;
• In April 2020, the Company qualified and received USD $652,500 from government funds in the US as part of the COVID-19 pandemic. As of June 30, 2020, the Company has approximately CAD $1.2 million in cash;
• In April, May and June 2020, the Company saw 3 consecutive months of profitability on an unaudited basis driven by improved operating margins from efforts in 2019 and Q1 2020, as well as growth in top line revenues;
• In June 2020, the Company amended its promissory note held by Merida Capital Partners, extending it to December 2022, reducing its interest rate of from 12% to 8%, payable in shares or cash and the company’s option and a forced conversion at a premium to the current market price;
• In July 2020, the Company launched the first in a series of monthly medical reports derived from real-world clinical treatments on a variety of healthcare conditions and modalities across the United States, Canada and United Kingdom.

Mr. Sekar continued, “What we have built in 2019 and the first quarter of 2020, allows us to accelerate our growth moving forward. We believe the expansion into traditional healthcare verticals is both accretive and prudent given the future role this company can play in the real-world evidence space. It also provides a huge opportunity to further grow and capitalize on one of the largest and underserviced segments of healthcare spending in the US. Our focus in 2020 and 2021 will be on growth from same services, growth from new services (SHG), and growth through accretive acquisitions.”